Press release archive 1999

Wednesday, 15 December 1999
ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW ASTHMA MEDICATION SYMBICORT® VIA EUROPEAN MUTUAL RECOGNITION AstraZeneca today announced that the regulatory application for Symbicort®, budesonide and formoterol in a single inhaler (Turbuhaler®) for maintenance therapy in asthma, has been submitted to the authorities in Sweden as the first step in the European Union's mutual recognition procedure. Applications for the new product will follow in early 2000 in further countries.
Monday, 13 December 1999
ZENECA AGROCHEMICALS AND CAMBRIDGE DISCOVERY CHEMISTRY ANNOUNCE COLLABORATION COLLABORATION    Cambridge Discovery Chemistry, formerly Cambridge Combinatorial, a wholly owned subsidiary of Oxford Molecular Group plc, and Zeneca Agrochemicals, the crop protection and plant science business of AstraZeneca, today (13th December) announced a major chemistry R&D collaboration.
Monday, 6 December 1999
ASTRAZENECA PROGRESSES KEY PRODUCTS AND AIMS TO DOUBLE PRODUCT PORTFOLIO VALUE EVERY FIVE YEARS HIGHLIGHTS
Wednesday, 17 November 1999
ASTRAZENECA ENTITLED TO INTERLOCUTORY* INJUNCTION TO PREVENT MARKETING OF A GENERIC VERSION OF OMEPRAZOLE IN ISRAEL AstraZeneca today announced that the Tel Aviv District Court has held that AstraZeneca is entitled to an interlocutory injunction in Israel based on the formulation patent, to prevent Dexcel Ltd. from marketing a generic omeprazole product.
Tuesday, 16 November 1999
ZENECA AGROCHEMICALS ANNOUNCES INVESTMENT IN MESOTRIONE CORN HERBICIDE Zeneca Agrochemicals today (16 November) announced its decision to invest $47 million in the formulation and manufacture of the new corn herbicide active ingredient mesotrione, to be produced at Zeneca's manufacturing facility at Cold Creek, Alabama, USA.
Friday, 12 November 1999
ASTRAZENECA - INTERLOCUTORY INJUNCTION TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT IN GERMANY DENIED AstraZeneca today announced that its request for an interlocutory injunction in Germany to prevent Azupharma GmbH from marketing a generic omeprazole version has been denied by the Appeal Court in Frankfurt. Omeprazole is the substance used in Losec®.
Wednesday, 27 October 1999
ASTRAZENECA DIVESTS TWO CARDIOVASCULAR MEDICINES IN SCANDINAVIAN AND EUROPEAN MARKETS TO COMPLY WITH EC MERGER CONDITIONS AstraZeneca today announced the partial divestment of two cardiovascular medicines, in Scandinavian and European markets, to comply with European Commission merger conditions set in approving the merger of Astra, of Sweden, and Zeneca, of the UK, earlier this year.
Thursday, 21 October 1999
ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW PPI VIA EUROPEAN MUTUAL RECOGNITION AstraZeneca today announced that a regulatory application for H199/18, a new proton pump inhibitor (PPI), has been submitted to authorities in Sweden, acting as rapporteur country in the European Union's mutual recognition procedure. The new pharmaceutical contains the active substance esomeprazole.
Monday, 18 October 1999
ASTRAZENECA's OMEPRAZOLE FORMULATION PATENTS AstraZeneca today announced that the Tel Aviv District Court has upheld the formulation patents for omeprazole. This follows an appeal by AstraZeneca and the Israeli company Unipharm. The District Court found that the inventions subject to the patents constituted a significant advance over prior art and that they were not obvious. Omeprazole is the substance used in Losec®.
Monday, 4 October 1999
ASTRAZENECA EXPANDS ACCESS TO INCYTE DATABASES AND BECOMES THE FIRST SUBSCRIBER TO INCYTE's LIFEEXPRESS RNA AND PROTEIN EXPRESSION DATABASE PROGRAM Zeneca and Incyte Pharmaceuticals, Inc. of Palo Alto, California announced today that AstraZeneca has expanded its access to Incyte's databases and will become the first subscriber to Incyte's LifeExpress™ expression database program.